Pfizer Downgrade: Bearish Options Trade Despite Signs of Rebound

Bullish Gator

Rick Ducat outlines Pfizer’s downgrade, near-52-week lows, and a bearish options strategy while noting technical signs that could fuel a rebound.

Editorial companion

What stands out

Rick Ducat flagged Pfizer after a downgrade, calling it an underperformer in healthcare and versus the S&P 500 (SPX), yet still pointed to some technical strength and pitched a bearish options trade. That contradiction matters because Pfizer’s reported averages show revenue down 8.6% year on year while average net income is up 59.1%, a gap that hides whether profits are durable or driven by one-time items. The clip pulls traders into a practical question: is the recent bounce, 20-day +3.5% with Relative Strength Index (RSI) 52.7, the start of a rebound or merely a spot to sell into?